Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight
23 nov. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight ...
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
07 déc. 2017 16h05 HE
|
Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
11 sept. 2017 06h00 HE
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...
Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
28 août 2017 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will...
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
08 juin 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration
07 déc. 2016 07h00 HE
|
Cascadian Therapeutics, Inc.
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...